This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gelmon, K. Articles by Harbeck, N. Search for Related Content PubMed PubMed Citation Articles by Gelmon, K. Articles by Harbeck, N.

The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer

^a British Columbia Cancer Agency, Vancouver, Canada; ^b Mount Hospital, Perth, Australia; ^c Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany

Key Words. Capecitabine • Metastatic breast cancer • Docetaxel • Paclitaxel • Trastuzumab • Bevacizumab

Correspondence: Nadia Harbeck, M.D., Ph.D., Department of Obstetrics and Gynecology, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany. Telephone: 49-89-4140-4596; Fax: 49-89-4140-4846; e-mail: nadia.harbeck{at}lrz.tum.de

Capecitabine is an important drug in the therapeutic armamentarium for metastatic breast cancer. A comprehensive worldwide clinical trial program involving >10,000 patients with locally advanced and metastatic breast cancer has provided evidence for the current treatment strategies. On the basis of data demonstrating consistent activity across several trials in patients with heavily pretreated breast cancer, capecitabine was approved in the U.S. in 1998 for the treatment of patients with metastatic disease resistant to paclitaxel and anthracycline-containing therapy, with later European Union approval for single-agent capecitabine in the metastatic setting. Capecitabine plus docetaxel (XT) was approved by the U.S. Food and Drug Administration for the treatment of metastatic breast cancer in 2001 on the basis of the large phase III trial comparing XT with docetaxel alone, which showed a survival advantage for combination therapy compared with single-agent therapy. This was shortly followed by European approval for the combination in metastatic breast cancer. The clinical utility of capecitabine in the management of breast cancer is supported by its convenient oral dosing schedule and favorable safety profile, as well as its excellent clinical activity in primary and metastatic breast cancer. Recently, clinical trials have studied single-agent capecitabine as first-line treatment and evaluated other capecitabine-containing combinations with cytotoxic and novel targeted agents.

This article has been cited by other articles:

				L. Chaigneau, B. Royer, D. Montange, T. Nguyen, T. Maurina, C. Villanueva, M. Demarchi, C. Borg, C. Fagnoni-Legat, J.-P. Kantelip, et al. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study Ann. Onc., November 1, 2008; 19(11): 1980 - 1981. [Full Text] [PDF]

				P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8. [Abstract] [Full Text] [PDF]

				J. A. Garcia-Saenz, M. Martin, and E. Diaz-Rubio Elementary, My Dear Watson J. Clin. Oncol., May 1, 2007; 25(13): 1815 - 1816. [Full Text] [PDF]